Business Context and Reporting Period
This Form 8-K reports the consummation of a business combination on September 12, 2023, between First Light Acquisition Group, Inc. ("FLAG") and Calidi Biotherapeutics, Inc. ("Calidi"). Following the merger, FLAG was renamed Calidi Biotherapeutics, Inc. and is now a Delaware corporation. The combined company's common stock and warrants began trading on the NYSE American under the symbols CLDI and CLDI WS, respectively. The filing also discloses the company's transition from shell company status to an operating entity.
Key Financial Metrics and Capital Structure
- Merger Consideration: Calidi security holders received approximately $250,000,000 in newly issued shares, plus a net debt adjustment of $23,756,000 related to Series B Financing.
- Shares Issued: A total of 27,375,600 shares of Common Stock were issued as merger consideration to Calidi security holders.
- Redemptions: 2,687,351 FLAG public shares were redeemed for approximately $28.2 million.
- Outstanding Shares: Immediately following the transaction, approximately 35,906,523 shares of Common Stock were issued and outstanding.
- Escalation Shares: Up to 18,000,000 additional shares are subject to an escalation mechanism based on stock price hurdles ($12, $14, $16, and $18) over specific trading periods. These shares are held in escrow and are non-voting until released.
- Ownership Structure: Post-transaction, Calidi stockholders own approximately 77.4%, former FLAG directors/officers/Sponsor own 15.4%, and public stockholders own 7.2%.
- Financial Statements: The filing incorporates unaudited interim financial statements for Calidi for the six months ended June 30, 2023, and pro forma combined financial information. Specific revenue, profit, or cash flow figures for the combined entity are not detailed in this text but are referenced in the Proxy Statement/Prospectus.
Material Changes and Corporate Actions
- Corporate Name Change: The registrant changed its name from First Light Acquisition Group, Inc. to Calidi Biotherapeutics, Inc.
- Share and Warrant Cancellation: The Sponsor and Metric agreed to cancel and forfeit for no consideration 222,907 shares and 1,485,001 Private Placement Warrants (collectively "Remaining Incentive Securities").
- Accounting Firm Change: The Audit Committee appointed Marcum LLP as the independent registered public accounting firm, effective September 12, 2023, replacing BDO USA, P.C. BDO had previously expressed substantial doubt regarding FLAG's ability to continue as a going concern prior to the merger.
- Board Composition: A new seven-member board was elected, divided into three staggered classes. Allan Camaisa and Scott Leftwich serve as Class III directors.
- Equity Plans: The 2023 Equity Incentive Plan and 2023 Employee Stock Purchase Plan were approved and became effective upon closing.
Guidance, Risks, and Contingencies
- Forward-Looking Statements: The filing contains projections regarding financial position and business strategy, which are not guarantees of performance.
- Key Risks:
- Failure to realize anticipated benefits of the business combination.
- Unanticipated costs related to the transaction.
- Regulatory approval risks for product candidates (oncolytic viruses and human stem cells).
- Risk that preclinical studies or clinical trials will not demonstrate safety and efficacy.
- Need for additional capital to achieve business goals.
- Potential inability to maintain listing on the NYSE American.
- Dividends: The company has not paid cash dividends and does not expect to pay any in the foreseeable future.
- Legal Proceedings: Information regarding legal proceedings is incorporated by reference from the Proxy Statement/Prospectus; no specific active litigation details are provided in this text.
Investor Verification Checklist
- Verify the pro forma financial information and liquidity position in the Proxy Statement/Prospectus (referenced in Item 9.01) to assess capital runway.
- Review the Escalation Share terms to understand potential future dilution if stock price targets ($12-$18) are met.
- Confirm the status of regulatory approvals for Calidi's product candidates, as this is a primary business risk.
- Examine the Series B Financing details and the $23.7 million net debt adjustment to understand the company's current debt obligations.
- Check the beneficial ownership table to confirm the concentration of control (Allan Camaisa holds 28.2% and the executive group holds 43.7%).